Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12838390 | 0.86 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL2653117 | 0.84 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL15888182 | 0.84 | TSHR (0.49) | ALDH1A1SMN1; SMN2TSHRMAPTHPGD | |
| SCHEMBL8010507 | 0.83 | ALDH1A1 (0.39) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL7018973 | 0.83 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL6814615 | 0.83 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL348559 | 0.82 | LMNA (0.51) | ALDH1A1SMN1; SMN2TSHRMAPTHPGD | |
| SCHEMBL2653067 | 0.82 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL2653869 | 0.81 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL1731610 | 0.81 | ALDH1A1 (0.38) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390668-A | Compound with ketoxime ether structure and application thereof | 复旦大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-115368306-B | HDAC inhibitor containing tetrahydroisoquinoline structure, composition and application thereof | 安徽中医药大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-110234656-B | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| CN-115368306-A | HDAC (Histone deacetylase) inhibitor containing tetrahydroisoquinoline structure, composition and application thereof | 安徽中医药大学 | 2022-11-22 | — | — | CN | disclosed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-0861843-B1 | Fluorescent ionophoric compounds with a cryptand/crown-ether portion and a coumarin portion, their preparation and their use for measuring metal cation concentrations | TERUMO CARDIOVASCULAR SYS (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-5958782-A | FLUORESCENT IONOPHORIC COMPOUND IS DISCLOSED THAT INCLUDES A COMPLEXING MOIETY, SUCH AS A CRYPTAND OR CROWN-ETHER PORTION, AND A FLUORESCING MOIETY SUCH AS A COUMARIN PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0861843-A2 | Fluorescent ionophoric compounds with a cryptand/crown-ether portion and a coumarin portion, their preparation and their use for measuring metal cation concentrations | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5434173-A | Administering to treat acne, psoriasis, eczema, dermatitis, and other skin disorders | ALLERGAN, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| US-5391753-A | Tumor inhibiting agents; useful for treating dermatological conditions and rheumatic illnesses | ALLERGAN, INC. (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0626955-A1 | HETEROARYL SUBSTITUTED PHENYLETHENYL COMPOUNDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1993016067-A1 | HETEROARYL SUBSTITUTED PHENYLETHENYL COMPOUNDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| US-4273782-A | FOR USE IN CARDIOVASCULAR DISORDERS AND COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | HDAC3 1985/4885HDAC4 2614/4885HDAC1 3062/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | HDAC3 1985/4885HDAC4 2614/4885HDAC1 3062/4885 |
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | HDAC3 1238/4885HDAC4 1841/4885HDAC1 2180/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | HDAC3 1929/4885HDAC4 2651/4885HDAC1 2814/4885 |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | HDAC3 1985/4885HDAC4 2614/4885HDAC1 3062/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | HDAC3 1985/4885HDAC4 2614/4885HDAC1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.